Weaning Off Citalopram
Citalopram should be tapered gradually rather than stopped abruptly, with dose reductions occurring over weeks to months using the smallest available dose decrements, and patients should be monitored closely for discontinuation symptoms throughout the taper.
FDA-Approved Tapering Guidance
The FDA label for citalopram explicitly states: "A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible" 1. If intolerable symptoms occur during dose reduction or discontinuation, resuming the previously prescribed dose should be considered, followed by a slower taper 1.
Discontinuation Syndrome Risk
Citalopram is associated with discontinuation syndrome, though to a lesser extent than paroxetine, fluvoxamine, or sertraline 2. The syndrome manifests with:
- Somatic symptoms: dizziness, fatigue, lethargy, myalgias, chills, headaches, nausea, vomiting, diarrhea, insomnia, imbalance, vertigo, sensory disturbances, paresthesias
- Psychological symptoms: anxiety, irritability, agitation 2
These symptoms typically emerge within 24-48 hours after missed doses or abrupt discontinuation 3 and are generally mild and self-limiting, lasting days to weeks 4, 5.
Recommended Tapering Schedule
Duration and Rate
- Taper over weeks to months, not days 4, 5
- A commonly cited approach is reducing by 10% of the original dose per week as a starting point, though slower tapers (e.g., 10% per month) may be better tolerated 6, 7
- For patients on long-term treatment (≥1 year), tapers should be individualized and may require several months 8
Dose Reduction Strategy
- Use the smallest available dose increments for reductions 2
- Avoid alternate-day dosing as a tapering strategy—this creates pronounced fluctuations in receptor occupancy and increases withdrawal risk 9
- Continue tapering to doses much lower than minimum therapeutic doses before complete cessation 10
- After reaching the smallest available dose, extend the interval between doses before stopping completely 8
Hyperbolic Tapering Approach
Recent evidence suggests that hyperbolic (exponential) tapering—where dose reductions become progressively smaller—may be more effective than linear tapers because it maintains more consistent receptor occupancy 10. This means larger initial dose reductions followed by increasingly smaller decrements as you approach zero.
Monitoring and Management
Patient Monitoring
- Monitor closely for discontinuation symptoms when reducing or stopping treatment 1
- Follow up at least monthly during the taper 8
- Watch for symptoms that could be mistaken for depression relapse 2, 3
Managing Withdrawal Symptoms
If withdrawal symptoms occur:
- Restart the previous dose that was tolerated 1, 5
- Slow the taper rate further 8
- Consider pausing the taper temporarily 8
- Provide symptomatic management as needed 5
Patient Education
- Educate patients that discontinuation symptoms are usually transient 3
- Distinguish withdrawal symptoms from relapse of underlying depression 2, 3
- Reassure patients while not minimizing their experience 11
Common Pitfalls to Avoid
- Do not use alternate-day dosing as a tapering method—this causes severe receptor occupancy fluctuations 9
- Do not stop at "minimum therapeutic doses"—continue tapering to much lower doses 10
- Do not rush the taper—guidelines recommending 2-4 week tapers show minimal benefit over abrupt discontinuation 10
- Do not mistake withdrawal for relapse—this leads to unnecessary long-term medication 10, 3
Special Considerations
- Citalopram has a shorter half-life than fluoxetine, making gradual tapering more important 2, 3
- The first dose reduction is critical—it must go well to establish patient confidence 12
- While only 8.9% of patients receive documented tapers in practice 12, all patients should receive at least a prescription for the lowest available dose before complete discontinuation